



Oct. 15, 2010


NinePoint Medical Adds Optical Coherence Tomography Technology Expert to Board of Directors

Cambridge, Mass. – October 15 2010— NinePoint Medical, an emerging leader in the development of in vivo pathology medical devices, today announced the appointment of Eric Swanson as a new member of its board of directors, effective immediately. Mr. Swanson's appointment expands NinePoint Medical's board of directors to four members. Mr. Swanson is currently a research affiliate at the Massachusetts Institute of Technology (MIT), a consultant for Draper Laboratory, and an advisor to high-tech startup companies covering a wide range of technologies, including biomedical imaging and optical components.

"Eric is widely considered to be a thought leader within the field of optical coherence tomography and telecommunications, and we believe his broad range of experience and expertise will meaningfully expand our board's capabilities," said Charles Carignan, president, chief executive officer and board member of NinePoint Medical. "As NinePoint continues to develop a suite of optical imaging devices focused on the convergence of the access, diagnosis and treatment paradigm for the GI tract, Eric's extensive business experience, contacts and technical know-how will bring a unique and relevant perspective to NinePoint Medical. We are pleased to welcome Eric to our team and look forward to his many contributions."

"I am excited to join NinePoint Medical's board and continue to build on my experience working with startups composed of great people, great technology, great market opportunities and, most importantly, the potential to make a major impact. NinePoint Medical is at an exciting stage, and its technology platform has the potential to greatly improve the diagnostic and treatment options available to the medical community," said Mr. Swanson. "I look forward to working closely with the rest of the board and management team to move NinePoint's innovative technology forward in development." Prior to his current roles as advisor and consultant, Mr. Swanson was the chief scientist at Sycamore Networks, which he co-founded. The company develops and markets intelligent optical switches and other products designed to create more effective communications networks and executed a successful NASDAQ initial public offering in 1999 that reached more than \$14 billion in market capitalization at the end of its first day of trading. Before founding Sycamore,

Mr. Swanson co-founded and was the chief technology officer of LightLab Imaging, a biomedical imaging company that commercialized OCT for a wide range of medical markets including cardiology and endoscopy. LightLab was ultimately acquired in 2010 by St. Jude Medical for \$100 million. Prior to LightLab Imaging, Mr. Swanson co-founded Advanced Ophthalmic Devices (AOD), a startup focused on ophthalmologic imaging using OCT. AOD was acquired in 1994 by Carl Zeiss Meditec, a leading ophthalmic instrumentation company, and served as a foundation for Zeiss's highly



successful world leading ophthalmic OCT product line. Prior to AOD, Mr. Swanson was an assistant group leader of research and development at the Lincoln Laboratory at the Massachusetts Institute of Technology for 15 years.

Mr. Swanson has authored more than 180 technical papers and holds more than 27 US patents and numerous foreign patents. He is a fellow of the OSA and senior member of the IEEE. In 1992 he received the prestigious Rank Prize for contributions to mankind in Opto-Electronics for his work in the field of OCT. Mr. Swanson holds a B.S. summa cum laude in electrical engineering from the University of Massachusetts at Amherst and an M.S. in electrical engineering from the Massachusetts Institute of Technology.

About NinePoint Medical, Inc.

NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo pathology devices focused on dramatically improving patient care. Through its proprietary optical frequency domain imaging (OFDI), a next-generation frequency domain optical coherence tomography, NinePoint intends to bridge the gap between the diagnosis and treatment of disease. With its advanced optical technology, OFDI will enable physicians and pathologists, for the first time, to view real-time, high resolution imaging of entire organs. Initially, NinePoint is focusing on devices that enable real-time screening and surveillance of the gastrointestinal (GI) tract for patients with Barrett's esophagus, one of the most common precursors to esophageal cancer. Eventually, NinePoint intends to develop medical devices that provide physicians with immediately actionable information and that will allow them to diagnose and treat patients during the same procedure. This convergence of access, diagnosis and treatment during one procedure is expected to improve patient experiences and outcomes, improve the efficiency of care and provide important savings to the healthcare system. Broader applications of NinePoint's technology are expected to follow in a variety of areas including pulmonary medicine, gynecology, urology and ENT. Headquartered in Cambridge, Mass., NinePoint is backed by Third Rock Ventures and Prospect Venture Partners. For more information, please visit www.ninepointmedical.com.